
Product Data Sheet

Product Name: 2,3-dihydrothieno-Thiadiazole Carboxylate
Cat. No.: GC13836

Chemical Properties

Cas. No. 152467-47-5

Chemical Name methylthieno[3,2-d][1,2,3]thiadiazole-6-carboxylate

SMILES O=C(OC)C1=CSC2=C1N=NS2

Formula $C_6H_4N_2O_2S_2$ M.Wt 200.2

Solubility $\leq 2\text{mg/ml}$ in ethanol; 30mg/ml in DMSO; 30mg/ml in dimethyl formamide Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure

Background

2,3-dihydrothieno-Thiadiazole Carboxylate is a CYP450 (CYP2E1 and CYP2B4) inhibitor.

The cytochrome P450 (CYP) enzymes are a superfamily of oxidative catalysts critical in the biosynthesis and metabolism of various endobiotics such as steroids and steroid hormones, the neurotransmitter nitric oxide, and vitamins A and D. The cytochrome P450 enzymes are also involved in the metabolism of xenobiotics including natural products, drugs, and other organic chemicals.

In vitro: As a 1,2,3-thiadiazole analog, 2,3-dihydrothieno-thiadiazole carboxylate could both inhibit and inactivate certain microsomal CYP450 enzymes (CYP2E1 and CYP2B4) at $100\ \mu\text{M}$, but not others (CYP1A2). Moreover, P450 2E1 was significantly more sensitive than P450 2B4 to mechanism-based inactivation by 2,3-dihydrothieno-thiadiazole carboxylate when compared by the difference in partition numbers and inactivation rate constants. Inactivation rate constants (k_{inact}) determined from plots of $1/k_{\text{obs}}$ versus

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

$1/[I]$ were 0.08 for 2E1 and 0.04 min⁻¹ for P450 2B4, with K_{is} of 0.1 and 2.0 mM, respectively. The difference in the oxidation of the monocyclic and bicyclic thiadiazoles might account for the ability of 2,3-dihydrothieno-thiadiazole carboxylate to function as a mechanism-based inactivator [1].

In vivo: Up to now, there is no animal in vivo data reported.

Clinical trial: So far, no clinical study has been conducted.

Reference:

[1] Babu, B. R. and Vaz, A.D.N. 1,2,3-thiadiazole: A novel heterocyclic heme ligand for the design of cytochrome P450 inhibitors. *Biochemistry* 36, 7209-7216 (1997).

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA
